LIMN — Liminatus Pharma, Inc. Class A Common Stock
Liminatus Pharma, Inc. operates as a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is based in LA Palma, California.
Company profile
- Sector: Healthcare
- Industry: Biotechnology
- Country: US
- Exchange: NASDAQ Global Select
- Employees: 3
- Website: https://liminatuspharma.com
Latest SEC filings for LIMN
- 8-K — 2026-05-27
- 8-K — 2026-05-20
- 10-Q — 2026-05-15
- 10-K — 2026-03-31
- 8-K — 2026-03-04
- 8-K — 2026-02-18
- 424B4 — 2026-02-18
- S-1 — 2026-02-11
- 8-K — 2026-01-26
- 8-K — 2025-11-25
Latest LIMN news
- — Liminatus Pharma regains Nasdaq compliance (seekingalpha_market)
Educational tool only — not investment advice.